The authors found that MYC levels were downregulated in two myeloma cell lines, which suggested that MYC itself could be a pharmacodynamic (PD) marker of BET inhibition, although its usefulness would be limited to hematologic tumors[107]. This evidence concerns the gene MYC and hematopoietic and lymphoid system neoplasm.